Deborah Dunsire


Deborah Dunsire is a medical doctor and pharmaceutical executive who has served as CEO of multiple research companies.

Career

At a 2013 career event at Bentley University, Dunsire remarked that she "...never intended to go into business. But after 9 months waiting for an ophthamology residency to begin, she instead applied to a position as a clinical researcher" with Novartis.

Novartis

Dunsire started her career with Novartis in 1988 as an Executive Director of clinical research. She later rose to become Senior Vice President of North American oncology. During her tenure, she was responsible for the launch of blockbuster cancer therapy Gleevec.

Millennium Pharmaceuticals

Dunsire was appointed CEO of Millennium Pharmaceuticals in 2005. She left the company in 2013 after it was acquired by Takeda.

EnVivo / FORUM Therapeutics / Xtuit

Dunsire served as the CEO for a Fidelty Biosciences-backed start-up, EnVivo Pharmaceuticals, starting in 2013. The company later changed its name to FORUM, developing late-state treatments for Alzheimer's Disease. When a Phase 3 clinical trial was unsuccessful, Dunsire left and joined Xtuit for one year.

H. Lundbeck A/S

Dunsire was appointed as the CEO of Lundbeck, a neuroscience-focused pharmaceutical company based in Denmark, in July 2018.

Awards